Hemostemix Inc. Stock Toronto S.E.

CA4236943060

Biotechnology & Medical Research

End-of-day quote Toronto S.E. 06/03/2013			5-day change	1st Jan Change
0.3750 ^CAD	-46.43%		-.--%	-

09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI

News in other languages: Hemostemix Inc.

10/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
23/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
09/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors: Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	10/02/2020
Christina Wu DFI	Director of Finance/CFO	-	05/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	14/10/2021

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	26/11/2019
Ronnie Hershmann BRD	Director/Board Member	67	09/02/2020
Loran Swanberg BRD	Director/Board Member	-	08/04/2020

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	15.86M 11.33M 9.87M 9.34M 8.49M 1.09B 15.94M 111M 43.03M 552M 42.58M 41.63M 1.77B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	18.72M 13.38M 11.65M 11.03M 10.02M 1.28B 18.81M 131M 50.79M 651M 50.26M 49.14M 2.08B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	83.37%	Yield 2024 *	-	Yield 2025	-

09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI
07-31	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-17	Hemostemix Inc. amended terms of the transaction	CI
05-29	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-25	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-21	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
05-01	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-01	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-19	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT

08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA	NE
08-12	Hemostemix : Dr. Ernst von Schwarz named PI of Hemostemix Longevity Clinical Trial	PU
08-12	Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial	NE
07-28	Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results	NE
07-23	Hemostemix : grants 6,280,000 options	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	-46.43%	-.--%	-	-	11.33M
WUXI APPTEC CO., LTD.	+1.76%	+3.88%	+46.85%	+101.12%	70.89B
ARGENX SE	-0.02%	+1.64%	+40.33%	+77.76%	62.32B
INSMED INCORPORATED	+1.14%	-2.59%	-14.37%	+365.92%	27.07B
BIONTECH SE	+2.95%	+2.34%	+0.52%	-12.74%	24.78B
GENMAB A/S	+1.05%	+8.41%	+27.67%	-12.87%	20.59B
PHARMAESSENTIA CORPORATION	-0.83%	-9.47%	+174.16%	+295.44%	15.52B
EXELIXIS, INC.	+3.01%	+1.85%	+44.63%	+168.18%	14.49B
SUMMIT THERAPEUTICS INC.	+2.43%	+4.24%	-2.05%	+847.59%	14.14B
MADRIGAL PHARMACEUTICALS, INC.	+1.00%	+0.24%	+28.02%	+203.83%	12.35B
Average	-3.39%	+1.64%	+38.42%	+226.02%	29.13B
Weighted average by Cap.	+1.24%	+2.50%	+36.98%	+163.49%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.87M -1.63M -1.54M -1.4M -179M -2.63M -18.36M -7.1M -91.01M -7.02M -6.87M -291M	-4.71M -3.37M -2.93M -2.78M -2.52M -323M -4.74M -33.08M -12.79M -164M -12.66M -12.37M -525M
Net Debt	4.23M 3.02M 2.63M 2.49M 2.26M 290M 4.25M 29.69M 11.48M 147M 11.36M 11.11M 471M	2.86M 2.04M 1.78M 1.69M 1.53M 196M 2.87M 20.08M 7.76M 99.52M 7.68M 7.51M 319M

Hemostemix Inc. Stock Toronto S.E.

Stocks

CA4236943060

Biotechnology & Medical Research

Valuation: Hemostemix Inc.

Latest news: Hemostemix Inc.

Press Releases: Hemostemix Inc.

News in other languages: Hemostemix Inc.

Quotes and Performance

Managers and Directors: Hemostemix Inc.

Bio Therapeutic Drugs

Financials

Company Profile